Evolent Health, Inc. (EVH) News
Follow Evolent Health, Inc. (EVH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Evolent Health Raises 2026 Adjusted EBITDA Forecast to $130M-$135M
Evolent renewed its largest Surgical Management customer contract for four years and reported two new revenue agreements, bringing its year-to-date total to seven new or renewed contracts. The company reiterated 2026 rev
EARNINGS | Nov 05, 2026, 02:04 PM UTC
M
Evolent Health Reports Third-Quarter Revenue of $725.37 Million
Revenue rose 51.3% year over year as the net loss narrowed. Growth reflected Performance Suite contract go-lives and expanded oncology services, partly offset by lower membership at certain health-plan clients and contra
EQUITY | Nov 05, 2026, 12:19 PM UTC
M
Evolent Health Backs 2026 Revenue at $2.6B-$2.7B
EARNINGS | Nov 05, 2026, 12:16 PM UTC
M
Evolent Announces Third-Quarter 2026 Results
EQUITY | Nov 05, 2026, 12:04 PM UTC
M
Evolent to release Q3 2026 financial results on Nov. 5, 2026
Evolent (EVH) plans to release its third quarter 2026 financial results on Thursday, November 5, 2026.
EQUITY | Oct 09, 2026, 08:38 PM UTC
L
EVH - TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation
EVH - TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation
NEWS | Sep 21, 2026, 02:02 PM UTC
L
Evolent Health Raises FY2026 Sales Guidance from $2.400B-$2.600B to $2.600B-$2.700B vs $2.503B Est
Evolent Health (NYSE: EVH ) raises FY2026 sales outlook from $2.400 billion-$2.600 billion to $2.600 billion-$2.700 billion vs $2.503 billion estimate.
EARNINGS | Aug 06, 2026, 11:06 AM UTC
L
EVH - Evolent Announces Second Quarter 2026 Results
EVH - Evolent Announces Second Quarter 2026 Results
EARNINGS | Aug 06, 2026, 11:01 AM UTC
L
EVH Downgrade from Buy to Neutral at Citi
EVH Downgrade from Buy to Neutral at Citi
EQUITY | Jul 23, 2026, 11:55 AM UTC
L
Evolent Health shares are trading lower after Truist Securities downgraded the stock from Buy to Hold rating and maintained the price target
Evolent Health shares are trading lower after Truist Securities downgraded the stock from Buy to Hold rating and maintained the price target at $7.
EQUITY | Jun 30, 2026, 02:08 PM UTC
L
Truist Securities Downgrades Evolent Health to Hold, Maintains Price Target to $7
Truist Securities analyst Jailendra Singh downgrades Evolent Health (NYSE: EVH ) from Buy to Hold and maintains the price target from $7 to $7.
EQUITY | Jun 30, 2026, 01:51 PM UTC